Skip to main content

Military Health System

DOD participates in new COVID-19 antibody combination prevention trial

Image of Woman gets blood drawn. Miranda Heilweil gets her blood drawn at Madigan Army Medical Center, Washington, one of five DOD sites where the STORM CHASER trial is studying the efficacy of an antibody product that could prevent COVID-19 in people who have been exposed to the virus within eight days. (U.S. Army photo by Janell Cain)

Recommended Content:

Coronavirus & the MHS Response | COVID-19 Vaccine Efforts

While the Military Health System continues to support the development and distribution of COVID-19 vaccines to counter the ongoing public health threat of the disease, it’s investing in other efforts to counter the SARS-CoV-2 virus.

One of those includes evolving therapeutics as part of the U.S. government’s COVID-19 response through clinical trials of a long-acting antibody combination medicine to prevent COVID-19 among people who have been exposed to the disease.

The intramuscular long-acting antibody product, called AZD7442 and developed by AstraZeneca, is undergoing a phase III clinical trial at five Department of Defense sites to study its efficacy among eligible MHS beneficiaries who have recently been exposed to others with SARS-CoV-2 infection.

“This study will run for one year, although interim and primary analyses will likely occur much earlier in 2021,” said Dr. Simon Pollett, associate scientific director and COVID-19 research area director at the Uniformed Services University of the Health Science’s (USU) Infectious Diseases Clinical Research Program (IDCRP).

Under the name STORM CHASER, Pollett’s program is coordinating teams of physicians, nurses, pharmacists, and clinical research staff at Tripler Army Medical Center in Hawaii, Madigan Army Medical Center in Washington, William Beaumont Army Medical Center in Texas, Naval Medical Center Portsmouth in Virginia, and USU in Maryland. The lead investigators at these sites are Army Col. Viseth Ngauy, Army Col. Anjali Kunz, Dr. Gina Kubicz, Navy Lt. Cmdr. Tida Lee, and Army Lt. Col. Jeffrey Livezey, respectively.

This study is designed to prevent the development of illness in people who have been exposed to COVID-19 in care homes and sites with enhanced risk of disease transmission, under the sponsorship of AstraZeneca with support from the U.S. health information technology and clinical research firm IQVIA. IDCRP is supported through a cooperative agreement with The Henry M. Jackson Foundation for the Advancement of Military Medicine.

Primarily, STORM CHASER seeks to determine if the antibody injection can prevent COVID-19 in people who were exposed to the SARS-CoV-2 virus – which causes the disease – within the last eight days, but have not yet developed symptoms, explained Pollett. “This may include those exposed by household contacts, in crowded working conditions, in health care settings, and other scenarios,” he added.

A secondary objective of the study is examining whether the antibody injection can reduce viral shedding in those who may develop the disease after receiving the injection, said Pollett. Viral shedding occurs when the virus replicates inside the body and is released to the environment, making the host person contagious to others.

“Reduced viral shedding may perhaps correlate with reduced transmissibility, but this requires further study,” said Pollett.

STORM CHASER also aims to see if individuals who receive the AZD7442 injection after SARS-CoV-2 exposure experience less severe symptoms of COVID-19. Likewise, the clinical trial seeks to explore “sequencing of breakthrough virus to look at antibody escape mutations,” said Navy Capt. Timothy Burgess, IDRCP director. This will help determine whether AZD7442 protects across a range of SARS-CoV-2 strains, including newly emerged variants.

AZD7442 contains infection-fighting proteins called monoclonal antibodies that work to neutralize the virus, thus preventing COVID-19. Each dose is given once as two intramuscular shots in each gluteal region, within eight days of exposure.

If clinical trials are successful and the product receives emergency use authorization from the Food and Drug Administration, this investigational product would become another tool to defeat the COVID-19 pandemic. Two vaccines, by Pfizer-BioNTech and Moderna, are available to the U.S. population older than 16 and 18 years of age, respectively, under FDA’s EUA, with three more vaccines, including AstraZeneca’s, currently in clinical trials.

The vaccines work inside the body by triggering the immune system to make antibodies that will block or kill the SARS-CoV-2 spike protein if it enters the body, which results in immunity to coronavirus. They are given to healthy individuals who have not been exposed to the virus to protect them against getting seriously ill from the disease if they become infected or exposed, and studies are still being conducted to gauge their ability to keep people from spreading the virus.

AZD7442 may provide very rapid protection against COVID-19 in individuals who have been exposed because it is given while the virus is incubating, said Burgess. But those who have already received the COVID-19 vaccine are not eligible to participate in the study.

“The investigational product is intended to provide rapid immunity after exposure, with up to six months of protection thereafter,” said Burgess. “STORM CHASER is examining the efficacy of this.”

If the study is successful in achieving its objective of preventing COVID-19 after exposure, the hope, according to Pollett, is that transmission chains will also be stopped by preventing such COVID-19 cases, but further study is required.

This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority in partnership with the Department of Defense; Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense; under Contract No. W911QY-21-9-0001.

If interested in participating in the STORM CHASER trial - please contact Julia Rozman at: julia.rozman.ctr@usuhs.edu.

You also may be interested in...

Ramstein Now Offers Novavax Vaccine

Article Around MHS
9/8/2022
Military medical gives Soldier a COVID-19 vaccine

The 86th Medical Group is now offering the Novavax COVID-19 vaccine, which has been authorized for emergency use by the U.S. Food and Drug Administration, to members 18 years and older in the Kaiserslautern Military Community.

Recommended Content:

Immunization Healthcare Division | COVID-19 Vaccine Efforts | Immunizations | Coronavirus

Latasha Smith: Warrior against COVID-19

Article Around MHS
2/18/2022
Military personnel looking at a patient's cardiac rhythm

Air Force Tech. Sgt. Latasha Smith, an Airman assigned to the 86th Operational Medical Readiness Squadron, was celebrated as Airlifter of the Week, Jan. 27, 2022, after leading the assault against COVID-19 for over a year.

Recommended Content:

Coronavirus & the MHS Response

COVID-19 therapeutics support DOD pandemic response

Article Around MHS
2/11/2022
Military personnel getting COVID-29 doses ready

The U.S. Army Medical Materiel Agency is helping to protect the operational force by distributing several new therapeutic options that help to lessen the symptoms of mild-to-moderate cases of COVID-19 and keep Soldiers, their families and beneficiaries out of the hospital.

Recommended Content:

Coronavirus & the MHS Response

COVID-19 Health Action Response for Marines continues to study long-term effects of COVID-19 on Marines

Article Around MHS
2/10/2022
Medical military personnel talking to a patient

A team composed of U.S. Navy medical personnel and civilian technicians based out of the Naval Medical Research Center in Silver Spring, Maryland, assembled during the initial outbreak of COVID-19 to study the short and long-term effects that the virus has on Marines. 

Recommended Content:

Coronavirus & the MHS Response

Getting up-to-date on your COVID-19 vaccine

Article Around MHS
2/8/2022
Military personnel giving the COVID-19 vaccine

The U.S. Guard Coast is that we have vaccines to help prevent serious illness if you contract COVID-19.

Recommended Content:

Coronavirus & the MHS Response

Oregon National Guard surging to support hospitals again

Article Around MHS
1/27/2022
Oregon Army National Guard touring a hospital

Hundreds of Oregon National Guard members are increasing support of hospitals throughout the state in their second hospital relief mission during the COVID-19 pandemic.

Recommended Content:

Coronavirus & the MHS Response | Readiness Capabilities

Public Health nurses offer insights on living with COVID-19 now, looking into future

Article Around MHS
1/25/2022
The Challenges of Living with COVID

One of the more challenging jobs for any public health professional is dealing with unpredictability inherent in outbreaks like the current COVID-19 pandemic.

Recommended Content:

Coronavirus & the MHS Response

Navy Hospital Corpsman steps into the breach in the war on COVID-19

Article Around MHS
1/18/2022
Hospitalman Hector Conde standing in front of a immunization office's refrigeration

First responders and those fighting on the medical battleground have earned well-deserved recognition for their efforts.

Recommended Content:

Coronavirus & the MHS Response

This is my Why

Article Around MHS
12/30/2021
Air Force Senior Airman Marcus Bullock poses for a photo after receiving his COVID-19 vaccination

Air Force Senior Airman Marcus Bullock stated his reason for getting the vaccine was to help his mother and son be able to have a play date again.

Recommended Content:

COVID-19 Vaccine Efforts | Coronavirus & the MHS Response

So others may breathe - Navy Medicine Respiratory Therapist cares for COVID casualties

Article Around MHS
12/13/2021
Military Health personnel posing for a picture

Navy Hospital Corpsman 2nd Class Tessa Hazard, a respiratory therapist, recently deployed to Alabama as a member of a COVID-19 response team.

Recommended Content:

Coronavirus & the MHS Response

Army Public Health Center provides update on Long COVID risks

Article Around MHS
12/1/2021
COVID19 Symptoms

According to the Centers for Disease Control and Prevention, Post-COVID conditions are a wide range of new, returning, or ongoing health problems people can experience four or more weeks after first being infected with the virus that causes COVID-19.

Recommended Content:

Coronavirus & the MHS Response

JTF Coyote begins pediatric COVID-19 clinics as adult booster vaccination numbers increase

Article Around MHS
11/23/2021
Military health personnel giving the COVID-19 vaccine

The Vermont National Guard now supports the state's response to the COVID-19 pandemic with vaccinations for youth in the 5 to 11 age group and booster clinics for the general adult population.

Recommended Content:

COVID-19 Vaccine Efforts | Coronavirus & the MHS Response

USECAF receives insight into COVID19 vaccinations at Reserve wing

Article Around MHS
10/8/2021
Under Secretary of the Air Force Gina Ortiz Jones visits with 433rd Airlift Wing members at Wilford Hall Ambulatory Surgical Center, Joint Base San Antonio-Lackland, Texas, Oct. 2, 2021.

Under Secretary of the Air Force Gina Ortiz Jones visited the 433rd Airlift Wing here to meet with Reserve Citizen Airmen leaders on mandatory COVID-19 vaccination efforts, Oct. 2, 2021.

Recommended Content:

COVID-19 Vaccine Efforts | Coronavirus & the MHS Response

Compassionate Caring with COVID Vax Commitment

Article Around MHS
10/6/2021
A  female doctor poses for a photo.

When pregnant patients have an appointment with Lt. Cmdr. Megan Northup at Naval Hospital Bremerton, they get more than a qualified and caring OB/GYN physician.

Recommended Content:

Coronavirus & the MHS Response | COVID-19 Vaccine Efforts

Health Promotion duo optimizes health on Incirlik Air Base

Article Around MHS
9/30/2021
Air Force Capt. Sydney Sloan, 39th Operational Medical Readiness Squadron health promotion element chief (right), and Air Force Senior Airman Gloriann Manapsal, 39th Operational Medical Readiness Squadron health promotion technician (left), promote making healthy choices at the Sultan’s Inn Dining Facility on Incirlik Air Base, Turkey.

The 39th Operation Medical Readiness Squadron health promotion team provides and integrates evidence-based programs to optimize the health and readiness, even during these unprecedented times.

Recommended Content:

Health Readiness & Combat Support | Total Force Fitness | Coronavirus & the MHS Response
<< < 1 2 > >> 
Showing results 1 - 15 Page 1 of 2
Refine your search
Last Updated: September 27, 2022
Follow us on Instagram Follow us on LinkedIn Follow us on Facebook Follow us on Twitter Follow us on YouTube Sign up on GovDelivery